This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bears are Losing Control Over Phibro (PAHC), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Phibro (PAHC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is it Apt to Hold Quest Diagnostics Stock in Your Portfolio Now?
by Zacks Equity Research
DGX stays on investors' radars due to its robust prospects in Advanced Diagnostics and progress in the acquisition strategy.
5 High Earnings Yield Value Stocks to Buy Amid Market Volatility
by Rimmi Singhi
Volatility looms with sticky inflation, a slowing economy and Trump's trade policies. Buy high-earnings-yield stocks like NUS, HRMY, PAHC, DAN and NRG.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is Veracyte Stock a Good Addition to Your Portfolio Right Now?
by Zacks Equity Research
VCYT stays on investors radar due to the strong performance of the Afirma and Decipher franchises.
Should Edwards Lifesciences Stock Remain in Your Portfolio Now?
by Zacks Equity Research
EW stock is on investors' radars due to the promising structural heart opportunities following the divestment of the Critical Care arm.
Is it the Right Time to Hold EYE Stock in Your Portfolio Now?
by Zacks Equity Research
National Vision continues to draw investors' attention with its strategic transformation efforts, while positive industry trends should favor its growth.
Zacks.com featured highlights include General Motors, Expedia Group, Phibro Animal Health and Pilgrim's Pride
by Zacks Equity Research
General Motors, Expedia Group, Phibro Animal Health and Pilgrim's Pride are part of the Zacks Screen of the Week article.
Should You Hold IDEXX Stock in Your Portfolio for Now?
by Zacks Equity Research
IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising.
ZBH Stock Hurt by Margin Concerns and Difficult Solvency
by Zacks Equity Research
Zimmer Biomet is suffering due to macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations.
Brainsway Ltd. Sponsored ADR (BWAY) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Brainsway (BWAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
4 PEG-Based Value Stocks to Shield Your Portfolio From Trade War
by Urmimala Biswas
Here are four PEG-driven GARP stocks, GM, EXPE, PAHC and PPC, which qualify our screening criteria.
Best Momentum Stocks to Buy for February 14th
by Zacks Equity Research
FINW, SFTBY and PAHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 14, 2025.
Why Phibro Animal Health (PAHC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
4 Stocks Trading Near 52-Week High With More Upside Potential
by Vasundhara Sawalka
Stocks like NFG, ENS, PAHC and C are seeing price strength and have a high chance of carrying the momentum forward.
Is Now the Right Time to Hold on to Charles River Stock?
by Zacks Equity Research
CRL's solid prospects in the DSA segment and strategic partnerships present a promising opportunity for investors.
New Strong Buy Stocks for February 14th
by Zacks Equity Research
FRSH, SFTBY, ATGE, FINW and PAHC have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2025.
Best Value Stocks to Buy for February 14th
by Zacks Equity Research
ATGE and PAHC made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 14, 2025.
Best Income Stocks to Buy for February 14th
by Zacks Equity Research
PAHC made it to the Zacks Rank #1 (Strong Buy) income stocks list on February 14, 2025.
Value, Growth and Momentum: DAN and PAHC Stocks Have it All
by Ethan Feller
Dana and Phibro Animal Health are two stocks with discounted valuations, strong earnings growth forecasts and top Zacks Ranks
HOLX's New Offerings Likely to Revive Stock Amid Macro Woes
by Zacks Equity Research
Hologic's Surgical business has been recording strong broad-based performance by expanding access to technologies into new global markets.
TMO Stock Set to Gain From The Launch of New Spatial Imaging System
by Zacks Equity Research
Thermo Fisher's Invitrogen EVOS S1000 Spatial Imaging System addresses the limitations of current fluorescent microscopy technologies.
Here's Why You Should Retain HOLX Stock in Your Portfolio Now
by Zacks Equity Research
Hologic's strength in the molecular diagnostics wing instills optimism among investors. Yet, a dull macroeconomic environment raises concerns.
ALGN Stock Gains on the Launch of Invisalign Palatal Expander in Turkey
by Zacks Equity Research
Align Technology commercially launches its Invisalign Palatal Expander System in Turkey after approval from TMMDA.